Brown Melinda purchased $7K of DTIL
Brown Melinda purchased 1,135 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.27 on 2026-09-25.
How this was made
The 30-second read
Why it matters
The filing provides a fresh data point on insider activity but its material impact is limited due to the modest transaction size.
Market read
A routine insider purchase with minimal market relevance; unlikely to affect short‑term price.
What to watch
Potential upcoming clinical trial data or regulatory updates could make the insider's stake more relevant.
Background
SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.
Ticker impact
Director Melinda Brown bought 1,135 shares of Precision Biosciences for $7,116, increasing her stake to 45,481 shares.
likely minimal upward pressure as market digests the purchase
The transaction is a routine 10b5‑1‑free purchase of under $10k; such small buys rarely affect price.
Market effects
None
None
None
Counterpoint
The purchase could be a signal of upcoming positive news, but the amount is too small to be meaningful.
Key entities
- CompanyPrecision Biosciences Inc.
Biotech firm developing RNA‑based therapeutics, ticker DTIL.
- InsiderMelinda Brown
Director of Precision Biosciences.
